We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-1.04%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$165M
AUM Growth
-$4.08M
Cap. Flow
+$2.01M
Cap. Flow %
1.22%
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54

Top Buys

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$805K
2
HAL icon
Halliburton
HAL
+$792K
3
CAT icon
Caterpillar
CAT
+$787K
4
STLD icon
Steel Dynamics
STLD
+$775K
5
BKNG icon
Booking.com
BKNG
+$775K

Top Sells

Rank Stock Value
1
NFLX icon
Netflix
NFLX
+$1.05M
2
VMC icon
Vulcan Materials
VMC
+$1.01M
3
CSGP icon
CoStar Group
CSGP
+$998K
4
LLY icon
Eli Lilly
LLY
+$967K
5
IR icon
Ingersoll Rand
IR
+$913K

Sector Composition

Rank Sector Weight
1 Healthcare 18.63%
2 Financials 17.26%
3 Technology 14.89%
4 Energy 9.42%
5 Consumer Discretionary 8.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVIR icon
376
Atea Pharmaceuticals
AVIR
$367M
$72.5K 0.04%
24,183
-2,403
-9% -$8.18K
CLDX icon
377
Celldex Therapeutics
CLDX
$2.94B
$72.4K 0.04%
2,631
-261
-9% -$8.18K
REPL icon
378
Replimune Group
REPL
$444M
$72.1K 0.04%
4,216
-415
-9% -$8.15K
ERAS icon
379
Erasca
ERAS
$6.23B
$71.9K 0.04%
36,494
-3,631
-9% -$9.3K
ATAI icon
380
AtaiBeckley Inc
ATAI
$2.66B
$71.7K 0.04%
55,554
-5,535
-9% -$9.48K
DYN icon
381
Dyne Therapeutics
DYN
$4.18B
$71.4K 0.04%
7,972
-797
-9% -$8.59K
ETNB
382
DELISTED
89bio
ETNB
$71.3K 0.04%
4,619
-465
-9% -$7.81K
NRIX icon
383
Nurix Therapeutics
NRIX
$2.46B
$70.8K 0.04%
9,011
-901
-9% -$8.23K
PLRX icon
384
Pliant Therapeutics
PLRX
$66.3M
$70.5K 0.04%
4,066
-403
-9% -$6.99K
KRTX
385
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$70K 0.04%
414
-39
-9% -$7.33K
RLAY icon
386
Relay Therapeutics
RLAY
$4.06B
$69.6K 0.04%
8,272
-820
-9% -$8.82K
EDIT icon
387
Editas Medicine
EDIT
$401M
$69.5K 0.04%
8,914
-891
-9% -$7.64K
NTLA icon
388
Intellia Therapeutics
NTLA
$1.54B
$69.3K 0.04%
2,192
-214
-9% -$8.3K
GERN icon
389
Geron
GERN
$917M
$67.9K 0.04%
32,005
-3,185
-9% -$8.64K
INBX
390
DELISTED
Inhibrx, Inc. Common Stock
INBX
$67.5K 0.04%
3,678
-366
-9% -$7.66K
CVAC
391
DELISTED
CureVac
CVAC
$66.4K 0.04%
9,723
-969
-9% -$8.56K
PNT
392
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$66.4K 0.04%
9,954
-985
-9% -$8.19K
PRTA icon
393
Prothena Corp
PRTA
$451M
$66.2K 0.04%
1,372
-141
-9% -$8.38K
ARVN icon
394
Arvinas
ARVN
$530M
$66K 0.04%
3,361
-338
-9% -$8.29K
SNDX icon
395
Syndax Pharmaceuticals
SNDX
$1.74B
$65.8K 0.04%
4,532
-451
-9% -$8.53K
FLNA
396
Filana Therapeutics
FLNA
$42.2M
$65K 0.04%
3,907
-386
-9% -$7.65K
EXAI
397
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$64.4K 0.04%
14,247
-1,421
-9% -$9.18K
CERE
398
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$63.2K 0.04%
2,895
-287
-9% -$7.18K
ALDX icon
399
Aldeyra Therapeutics
ALDX
$98.3M
$63.2K 0.04%
9,460
-941
-9% -$6.98K
ALLO icon
400
Allogene Therapeutics
ALLO
$635M
$62.9K 0.04%
19,835
-1,978
-9% -$8.67K
14 15
16
17 18

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q3 2023 Portfolio in Review

As of Q3 2023, Virtus ETF Advisers held 488 positions worth $165M, down 2.4% from $169M the previous quarter. Its ten largest holdings account for 6.1% of the portfolio.

Virtus ETF Advisers's Q3 2023 filing shows 53 new, 73 increased, 307 reduced and 54 closed positions. Its largest new stake was Alphabet (Google) Class A: 6,222 shares worth $814K. The largest sale was Netflix, an estimated $1.05M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 28% a quarter earlier, followed by Financials and Technology.

  • Virtus ETF Advisers's largest Q3 2023 buy was Alphabet (Google) Class A: 6,222 shares worth $814K.
  • Virtus ETF Advisers added most to Coterra Energy in Q3 2023, an estimated $732K increase.
  • Virtus ETF Advisers's biggest Q3 2023 reduction was Incyte, cutting an estimated $701K.
  • Virtus ETF Advisers fully exited Netflix in Q3 2023, selling an estimated $1.05M.
  • Virtus ETF Advisers's ten largest holdings make up 6.1% of its $165M portfolio in Q3 2023.
  • Virtus ETF Advisers opened 53 new positions and closed 54 in Q3 2023.
  • Virtus ETF Advisers's portfolio value fell 2.4% quarter-over-quarter to $165M.

Based on Virtus ETF Advisers's 13F filing for Q3 2023, filed 7 Nov 2023.